Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A

Trial Profile

A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Damoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms PROTECT VIII extension; PROTECT-VIII
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 16 Jul 2019 Results (n=16) assessing patient-reported benefits in hemophilia A patients, published in The Patient - Patient-Centered Outcomes Research.
    • 12 Jul 2019 This trial was completed in Austria, according to European Clinical Trials Database.
    • 26 Jun 2019 According to a Bayer media release, long-term data from the PROTECT VIII extension study will be presented during the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH, July 6th-10th, 2019 in Melbourne, Australia).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top